Search clinical trials for: P1101

Total 858 results

PharmaEssentia

Recruiting

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Essential Thrombocythemia

United States, Canada
PharmaEssentia

Completed

Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects

Healthy Volunteers

Canada
PharmaEssentia

Recruiting

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Polycythemia Vera

United States, Canada
PMG Pharm Co., Ltd

Recruiting

A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis

Knee Osteoarthritis

Korea, Republic of
PMG Pharm Co., Ltd

Completed

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Arthritis

Korea, Republic of
PharmaEssentia Japan K.K.
PharmaEssentia

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

Australia
PharmaEssentia

Not yet recruiting

Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Low-Risk Polycythemia Vera (PV)

Polycythemia Vera | Myeloproliferative Neoplasm
PMG Pharm Co., Ltd

Completed

Drug-Drug Interaction Between PK101-001 and PK101-002

Arthritis

Korea, Republic of
PharmaEssentia

Completed

Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection

Hepatitis C, Chronic

Taiwan
Patara Pharma

Completed

Treatment of Refractory Chronic Cough With PA101

Refractory Chronic Cough

Netherlands, United Kingdom
EXACT Therapeutics AS

Recruiting

PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin (ACT)

Colorectal Cancer | Solid Tumor

United Kingdom, Norway
MacuCLEAR, Inc.

Terminated

Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration

Nonexudative Age Related Macular Degeneration

United States
PharmaEssentia

Recruiting

The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection

Chronic Hepatitis B Infection | Chronic Hepatitis D Infection

Taiwan
Taivex Therapeutics Corporation

Terminated

Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
MacuCLEAR, Inc.

Completed

A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD

Age-Related Macular Degeneration

United States
TRF Pharma, Inc

Terminated

TRF-1101 Assessment in Sickle Cell Disease

Sickle Cell Disease

United States
Taivex Therapeutics Corporation

Active, not recruiting

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
Taivex Therapeutics Corporation

Completed

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
Karus Therapeutics Limited

Completed

The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

Lymphoma, B Cell

United States
Rhodes Pharmaceuticals, L.P.
ORA, Inc.

Completed

Safety and Efficacy of PG101 for Dry Eye Syndrome (PG101)

Dry Eye Syndrome

United States
TG Therapeutics, Inc.

Recruiting

Study to Evaluate Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab (ENHANCE)

Relapsing Multiple Sclerosis

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Ulcerative Colitis

United States, Georgia, Germany, Hungary, Moldova, Republic of, Poland, Ukraine, United Kingdom
Panolos Bioscience

Recruiting

Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent

Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Gastric Cancer | Solid Tumor | Advanced Solid Tumor | Solid Tumor, Adult

Korea, Republic of
National Taiwan University Hospital
PharmaEssentia

Recruiting

Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

Chronic Hepatitis B Virus Infection

Taiwan
TG Therapeutics, Inc.

Completed

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) (GENUINE)

Chronic Lymphocytic Leukemia

United States, Israel
Weill Medical College of Cornell University
TG Therapeutics, Inc.

Terminated

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Chronic Lymphocytic Leukemia | CLL/SLL | CLL Progression

United States
Chong Kun Dang Pharmaceutical

Completed

CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis

Anemia of Chronic Kidney Disease
Academia Sinica, Taiwan
National Taiwan University Hospital; National Cheng-Kung University Hospital

Withdrawn

Autologous BMMNC Combined With HA Therapy for PAOD

Peripheral Arterial Occlusive Disease | Critical Limb Ischemia

Taiwan
TG Therapeutics, Inc.

Terminated

A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304

Chronic Lymphocytic Leukemia

United States, Poland, Italy, United Kingdom
AOP Orphan Pharmaceuticals AG

Completed

Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (PEGINVERA)

Polycythemia Vera

Austria
PharmaDax Inc.
Glia, LLC

Enrolling by invitation

Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study

Keratoconjunctivitis Sicca | Dry Eye Syndrome

Taiwan
MacuCLEAR, Inc.

Unknown

Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration (McCP2/3)

Non-Exudative Age Related Macular Degeneration

United States
University of KwaZulu
King's College London; Department for International Development, United Kingdom and other collaborators

Completed

Strengthening Mental Health Care in Chronic Care Patients With Hypertension. A Cluster Randomised Control Trial

Depression | Hypertension

South Africa
Chong Kun Dang Pharmaceutical
Seoul National University Hospital

Completed

Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers

Anemia

Korea, Republic of
National Taiwan University Hospital

Not yet recruiting

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities

COVID-19

Taiwan
PharmaEssentia Japan K.K.

Recruiting

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Polycythemia Vera (PV)

Japan
Chong Kun Dang Pharmaceutical
Seoul National University Hospital

Completed

Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers

Anemia

Korea, Republic of
National Taiwan University Hospital

Completed

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.

COVID-19

Taiwan
TG Therapeutics, Inc.

Completed

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
W.L.Gore & Associates

Completed

Multi-center Study for Stent Graft System for Peripheral Artery (VJH11-01)

Peripheral Arterial Disease

Japan
SymBio Pharmaceuticals

Completed

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
MacuCLEAR, Inc.

Completed

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

Nonexudative Age-related Macular Degeneration

United States
Patara Pharma

Completed

Treatment of Indolent Systemic Mastocytosis With PA101

Systemic Mastocytosis | Mastocytosis | Indolent Systemic Mastocytosis

France, Germany, Spain, Italy, Netherlands
TG Therapeutics, Inc.

Terminated

Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

Follicular Lymphoma | Small Lymphocytic Lymphoma

United States
TWi Biotechnology, Inc.

Recruiting

Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients With Granuloma Annulare

Granuloma Annulare

United States
Gilead Sciences

Terminated

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States

3

Subscribe